Compare AbCellera Biologics Inc (ABCL) vs Waste Management, Inc. (WM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Waste Management, Inc. — how do they compare? AbCellera Biologics Inc trades at $7.13 (market cap $2.35B), while Waste Management, Inc. trades at $236.21 (market cap $95.26B). The key difference: Waste Management, Inc. is far larger — about 40.5× AbCellera Biologics Inc's market cap, and Waste Management, Inc. pays a 1.49% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | WM | |
|---|---|---|
Market Cap | $2.35B | $95.26B |
Sector | Health | Industrials |
52-Week High | $8.12 | $246.51 |
52-Week Low | $2.78 | $196.77 |
Enterprise Value | $1.99B | $117.99B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
WM trades at $237.21, up 2.96% today and near its 52-week high of $248.13. The stock shows bullish technical signals with strong moving averages and positive momentum indicators. Fundamentally, revenue grew to $25.20B in 2025 with a net income margin of 10.99%, though recent quarters saw mixed earnings results. Analyst consensus is bullish with a $261 price target, and the company maintains a solid dividend with recent payout of $0.95 per share.
Outlook remains positive driven by pricing discipline and renewable energy initiatives, but risks include elevated valuation multiples and debt levels. The stock offers stability through economic cycles but faces execution risks in maintaining margin growth amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
